Endogenous Opioid Peptides
The endogenous peptide ligands of the mu, delta, and kappa opioid receptors — the enkephalins (Hughes & Kosterlitz 1975), beta-endorphin, dynorphin (Goldstein 1979), endomorphin-1 and -2, nociceptin/orphanin FQ, plus food-derived exorphins (casomorphin) and the indirect opioid analgesic kyotorphin. The neurobiological basis of endogenous pain modulation, reward, and stress response.
Endogenous opioid peptides are the body's natural ligands for the mu, delta, and kappa opioid receptors — the same receptors targeted by morphine, fentanyl, and other opioid analgesics. The family was launched by John Hughes and Hans Kosterlitz's 1975 isolation of the enkephalins (Met-enkephalin and Leu-enkephalin) from porcine brain at the University of Aberdeen, with the foundational Nature paper establishing that the brain produces its own pentapeptide opiate-like agonists (Hughes et al., Nature 1975, PMID 1207728). The discovery transformed opioid pharmacology from a story about plant alkaloids and synthetic narcotics into a story about endogenous neuropeptide systems — and earned Hughes and Kosterlitz a share of the 1978 Albert Lasker Award alongside Solomon Snyder and Eric Simon. Avram Goldstein extended the family with the 1979 PNAS paper on dynorphin (Goldstein et al., PMID 230519), the kappa-opioid-selective endogenous peptide that is paradoxically more potent than the enkephalins and produces a partly distinct pharmacological profile. Subsequent work added beta-endorphin (the 31-residue POMC-derived mu/delta agonist), endomorphin-1 and endomorphin-2 (the highly mu-selective tetrapeptides characterized by Zadina in 1997), nociceptin/orphanin FQ (the orphan-receptor-related opioid-like peptide that does not bind classical mu/delta/kappa), nocistatin (the nociceptin counter-regulator), and various tissue-specific and species-specific members.
The family also includes peptides at the periphery of strict 'endogenous opioid' definition: kyotorphin (the indirect opioid analgesic dipeptide that triggers Met-enkephalin release rather than binding opioid receptors directly), opiorphin (the salivary peptide that potentiates endogenous opioid effects through enkephalinase inhibition), and food-derived exorphins like casomorphin (the milk-protein-derived opioid-receptor agonist of A1-vs-A2-milk-debate fame). Dermorphin (the mu-selective agonist from amphibian skin) and substance P (a related neuropeptide that modulates opioid signaling without being itself opioid) sit adjacent to the family.
This page is the family-level pillar covering the endogenous opioid peptide class as a whole. For individual peptide pages with full evidence ratings, dosing, references, and pharmacological detail, follow the links to each member below.
Peptides in Endogenous Opioid Peptides
Beta-Endorphin
Endogenous Opioid Peptide / POMC Fragment
The 31-amino-acid endogenous opioid peptide cleaved from POMC in the pituitary and hypothalamus. The canonical 'endorphin' of popular science — invoked to explain runner's high, placebo analgesia, and acupuncture — though modern evidence has substantially weakened the classical runner's-high story.
Dynorphin
Endogenous Opioid Peptide
A family of endogenous opioid peptides derived from the prodynorphin (PDYN) gene that are selective agonists at the kappa-opioid receptor (KOR), best known as the dysphoric, aversive, stress-induced counterpart to the euphoric mu-receptor-preferring beta-endorphin system, and the biological target of the new generation of KOR-antagonist antidepressants (aticaprant, navacaprant).
Casomorphin
Food-Derived Peptide
A family of opioid-active peptides released by gastrointestinal digestion of bovine beta-casein, isolated by Brantl, Henschen, Teschemacher, and colleagues at the Max-Planck-Institut für Psychiatrie in 1979 — the seven-residue beta-casomorphin-7 (BCM-7) is the most studied member, central to the long-running A1 versus A2 milk debate, and the canonical example of an exogenous food-derived (exorphin) opioid peptide.
Endomorphin-1
Endogenous Opioid Peptide
An endogenous tetrapeptide (Tyr-Pro-Trp-Phe-NH2) discovered by James Zadina at Tulane in 1997 that is the most selective and potent natural agonist of the mu-opioid receptor identified to date — pharmacologically extraordinary, structurally unrelated to the YGGFL enkephalin family, and central to ongoing efforts to design opioid analgesics with reduced respiratory depression and abuse liability.
Kyotorphin
Neuropeptide
An endogenous analgesic dipeptide (L-tyrosyl-L-arginine) discovered in 1979 by Hiroshi Takagi's group at Kyoto University and named for the city, producing morphine-like analgesia in rodent models through a Met-enkephalin-releasing mechanism rather than direct opioid receptor binding — one of the smallest endogenous neuropeptides and an enduringly studied alternative-analgesic candidate.
Nociceptin
Endogenous Neuropeptide / NOP Receptor Ligand
A 17-amino-acid endogenous neuropeptide discovered in 1995 as the natural ligand of the orphan opioid-like receptor (now the NOP receptor), cleaved from the same prepronociceptin precursor as nocistatin but with functionally opposing pain pharmacology.
Opiorphin
Endogenous Enkephalinase Inhibitor
An endogenous human five-amino-acid peptide (Gln-Arg-Phe-Ser-Arg) discovered in 2006 by Catherine Rougeot and colleagues at the Institut Pasteur — a dual ectopeptidase inhibitor that simultaneously blocks neutral endopeptidase (neprilysin) and aminopeptidase N to prevent enkephalin degradation, thereby potentiating endogenous mu/delta-opioid signaling. Reported as a non-addictive endogenous analgesic with morphine-comparable potency in rodent models, with stabilized analogs (STR-324) advancing toward clinical pain indications.
Dermorphin
Mu-Opioid Receptor Agonist
A naturally occurring heptapeptide from frog skin and one of the most potent mu-opioid receptor agonists known, approximately 40 times more potent than morphine.
Nocistatin
Endogenous Neuropeptide
A neuropeptide encoded in the same prepronociceptin gene as nociceptin/orphanin FQ that functionally opposes nociceptin's actions — attenuating allodynia and hyperalgesia in animal models through a receptor system distinct from the NOP receptor.
Other members of the class
Met-enkephalin (Tyr-Gly-Gly-Phe-Met)
One of the two original endogenous opioid peptides isolated by Hughes and Kosterlitz in 1975. Five-residue peptide with delta-preferring activity at mu/delta opioid receptors. Not currently tracked as standalone peptide entry in the directory.
Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu)
The second of the two original endogenous opioid peptides isolated by Hughes and Kosterlitz in 1975. Differs from Met-enkephalin only at position 5 (Leu vs Met). Similar pharmacology — delta-preferring at mu/delta receptors.
Endomorphin-2 (Tyr-Pro-Phe-Phe-NH2)
Companion endomorphin to endomorphin-1, with similar mu-receptor selectivity but slightly different sequence. Tracked at the endomorphin-1 peptide page since the two are conventionally discussed together.
Dynorphin B and big dynorphin
Other prodynorphin-derived peptide products with kappa-opioid receptor activity. Less prominent in the published opioid pharmacology literature than dynorphin A.
Difelikefalin (Korsuva)
Selective peripherally-restricted kappa-opioid agonist FDA-approved 2021 for uremic pruritus in hemodialysis patients. Niche clinical translation of the kappa-opioid pharmacology pioneered by dynorphin discovery. Tracked separately at /peptides/difelikefalin.
Shared mechanism
The endogenous opioid family signals through three classical opioid receptors — mu (MOR/OPRM1), delta (DOR/OPRD1), and kappa (KOR/OPRK1) — plus the related nociceptin receptor (NOP/OPRL1). All four are class A G-protein-coupled receptors that couple primarily to Gi/o, lowering cAMP, activating inwardly rectifying potassium channels, inhibiting voltage-gated calcium channels, and producing the characteristic neuronal hyperpolarization and reduced neurotransmitter release of opioid signaling. The receptors share approximately 60% sequence identity but differ in tissue distribution, ligand selectivity, and downstream signaling balance.
Receptor selectivity defines the pharmacological profile of each family member. The enkephalins (Met-enkephalin, Leu-enkephalin) bind delta and mu receptors with comparable affinity, with somewhat greater delta selectivity. Beta-endorphin binds mu and delta receptors with high affinity. Dynorphin A is the principal endogenous kappa-opioid agonist with high kappa selectivity. Endomorphin-1 and endomorphin-2 are the most mu-selective endogenous opioids characterized to date. Nociceptin/orphanin FQ binds the NOP receptor exclusively, not the mu/delta/kappa classical opioid receptors. The diverse receptor profiles produce diverse pharmacological effects: mu agonism dominates classical analgesia and the reward circuitry; delta agonism contributes to mood effects and may have less abuse-liability; kappa agonism produces dysphoria, sedation, and antinociception; NOP agonism modulates stress responses and pain sensitivity through partly distinct circuits.
The peptides are biosynthesized as cleavage products of larger precursor proteins. Met-enkephalin and Leu-enkephalin derive from proenkephalin (and Met-enkephalin is also a fragment of POMC). Beta-endorphin derives from POMC. Dynorphin derives from prodynorphin. Endomorphin-1 and endomorphin-2 do not have an identified precursor gene — one of the open questions of endogenous opioid biology. Nociceptin derives from prepronociceptin, which also produces nocistatin as a separate cleavage product.
Kyotorphin's mechanism is uniquely indirect — it does not bind opioid receptors but instead triggers Met-enkephalin release from enkephalinergic neurons, with the released enkephalin then binding mu and delta receptors to produce analgesia. Opiorphin inhibits enkephalinase (membrane-bound aminopeptidase that degrades enkephalins) and thereby prolongs endogenous Met-enkephalin signaling. Casomorphin and the food-derived exorphins bind mu opioid receptors directly but with low-to-moderate affinity and limited bioavailability from dietary exposure.
History & discovery
The endogenous opioid story emerged in the early 1970s from converging lines of work. Lars Terenius in Sweden, Solomon Snyder and Candace Pert in Baltimore, and Eric Simon in New York characterized the brain opioid receptor in 1973 — establishing that morphine binds specific high-affinity sites in the central nervous system, and implying that endogenous ligands for those sites must exist. The race to isolate those ligands was won by John Hughes and Hans Kosterlitz at the University of Aberdeen, working with porcine brain extracts and using the guinea pig ileum and mouse vas deferens isolated-tissue preparations as bioassays for opiate-like activity. The 1975 Nature paper (Hughes et al., 'Identification of two related pentapeptides from the brain with potent opiate agonist activity,' PMID 1207728) reported isolation, sequencing, and pharmacology of Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) — the founding members of the endogenous opioid peptide family.
Beta-endorphin's discovery followed quickly. The 31-residue peptide had been characterized as a beta-lipotropin fragment by Choh Hao Li at UC San Francisco, and its opiate-like activity was recognized as the enkephalin work was unfolding. Beta-endorphin was identified as the C-terminal fragment of beta-lipotropin (residues 61-91), which is itself a fragment of the larger proopiomelanocortin (POMC) precursor — the same precursor that produces ACTH, alpha-MSH, and other peptides through tissue-specific differential processing. Beta-endorphin signaling at mu and delta receptors produces the characteristic mu-opioid analgesic effect with a longer plasma half-life than the enkephalins.
Dynorphin emerged from Avram Goldstein's group at Stanford with the 1979 PNAS paper (Goldstein A et al., 'Dynorphin-(1-13), an extraordinarily potent opioid peptide,' PMID 230519). Dynorphin A is a 17-residue peptide derived from the prodynorphin precursor, with the unique property of binding kappa-opioid receptors with high selectivity — making it the endogenous kappa agonist counterpart to beta-endorphin's mu/delta activity and the enkephalins' delta/mu activity. Dynorphin's pharmacology is partly distinct from the mu/delta opioid story: kappa agonism produces dysphoria rather than the euphoria of mu agonism, contributes to stress responses, and has been implicated in addiction circuitry differently from the mu-receptor reward pathways.
Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) were characterized by James Zadina and colleagues at Tulane and the New Orleans VA in 1997. The two highly mu-selective tetrapeptides bind mu-opioid receptors with greater selectivity than any other endogenous opioid peptide, but the gene encoding them has not been definitively identified — leaving their biosynthetic origin one of the open questions of endogenous opioid biology. Nociceptin/orphanin FQ was characterized in parallel by Meunier and Reinscheid in 1995 as the endogenous ligand for the orphan opioid-related receptor ORL1 (now NOP receptor) — a 17-residue peptide that does not bind mu/delta/kappa receptors and produces a distinctive pharmacological profile. Nocistatin emerged as a counter-regulator of nociceptin signaling.
Food-derived exorphins extended the family beyond strict endogenous origin. Casomorphin (the milk-protein-derived opioid agonist isolated by Brantl, Henschen, and Teschemacher at the Max-Planck-Institut in 1979) and gluten-derived gluteomorphins demonstrated that dietary protein digestion releases peptides with mu-opioid activity — the basis for the A1-vs-A2-milk debate and the broader 'exorphin' literature. Kyotorphin (the indirect opioid analgesic dipeptide isolated by Hiroshi Takagi at Kyoto University in 1979) and opiorphin (the salivary peptide that potentiates endogenous opioid effects via enkephalinase inhibition) round out the family with mechanistically distinct entries.
State of evidence
Evidence in this class is extensively developed in basic neuroscience but limited in direct therapeutic translation. The endogenous opioid peptides are well-characterized in their receptor pharmacology, anatomical distribution, and functional contributions to pain modulation, reward, stress, and other behaviors — five decades of research since the 1975 Hughes/Kosterlitz discovery have produced one of the most thoroughly mapped neuropeptide systems in modern neuroscience. The translational pharmacology has produced classical opioid analgesics (morphine, fentanyl, oxycodone — small-molecule mu agonists) and various selective receptor agonists and antagonists used as research tools and (for some) clinical agents.
What the family has not produced is a major endogenous-opioid-peptide therapeutic. The peptides are not used directly as analgesics because of poor blood-brain-barrier penetration, rapid plasma degradation by aminopeptidases and endopeptidases, and the existence of well-characterized small-molecule alternatives. Selective kappa-opioid agonists (difelikefalin / Korsuva, FDA-approved 2021 for uremic pruritus in hemodialysis patients) and related agents have produced niche clinical translations. The opioid-class clinical landscape continues to be dominated by small-molecule mu agonists for pain plus opioid antagonists (naloxone, naltrexone) and partial agonists (buprenorphine) for addiction medicine and overdose reversal.
The 'endogenous opioid' framing is more important conceptually than therapeutically. The discovery established that the brain has its own pain-modulating system, defined the receptor pharmacology that has guided opioid drug development for half a century, and continues to underlie research on stress, reward, addiction, and chronic pain. For patients, the practical clinical takeaway is that endogenous opioid peptides themselves are not therapeutics, but understanding the system informs how morphine-class drugs work and why their pharmacology produces the effects (analgesia, euphoria, respiratory depression, tolerance, dependence) that define modern opioid medicine.
How members compare
Within the family, the principal axes are receptor selectivity (mu-selective endomorphins vs delta-preferring enkephalins vs kappa-selective dynorphins vs NOP-specific nociceptin) and biosynthetic origin (POMC for beta-endorphin, proenkephalin for the enkephalins, prodynorphin for dynorphin, prepronociceptin for nociceptin and nocistatin). Endomorphins remain mechanistically distinct because their precursor gene has not been identified.
Outside the endogenous opioid family, the closest comparators are the small-molecule opioid analgesic class (morphine, oxycodone, hydromorphone, fentanyl, methadone, tramadol — mu agonists with various pharmacokinetic profiles), opioid antagonists (naloxone, naltrexone — for overdose reversal and addiction medicine), partial agonists (buprenorphine — for addiction medicine and chronic pain), and selective kappa or NOP agents in development. The CGRP-targeting biologics (erenumab, fremanezumab, galcanezumab) for migraine address pain through a different mechanism. Non-opioid pain pharmacology (NSAIDs, anticonvulsants for neuropathic pain, antidepressants for chronic pain, biologic agents for inflammatory pain) is the broader pain-management context within which endogenous opioid biology sits as the receptor pharmacology underlying classical opioid drugs rather than as a discrete therapeutic class.
Frequently asked questions
What's the difference between enkephalins, endorphins, and dynorphins?
All three are endogenous opioid peptide classes, but they differ in length, biosynthetic origin, and receptor selectivity. The enkephalins (Met-enkephalin and Leu-enkephalin) are 5-residue pentapeptides derived from proenkephalin (and Met-enkephalin also from POMC), with delta-preferring activity at mu/delta opioid receptors. Beta-endorphin is a 31-residue peptide derived from POMC, with high-affinity mu and delta receptor binding and longer plasma half-life than the enkephalins. Dynorphin A is a 17-residue peptide derived from prodynorphin, with high-affinity kappa-opioid receptor selectivity that distinguishes it from the mu/delta-focused enkephalin and beta-endorphin pharmacology. The three classes together cover the principal endogenous-opioid receptor activities — kappa from dynorphin, mu/delta from beta-endorphin and enkephalins.
Are endogenous opioid peptides used as drugs?
Generally no. The endogenous opioid peptides themselves are not used clinically because of poor blood-brain-barrier penetration, rapid plasma degradation by aminopeptidases and endopeptidases, and the existence of well-characterized small-molecule mu-opioid alternatives (morphine, fentanyl, oxycodone, hydromorphone, methadone). The 'endogenous opioid' literature is overwhelmingly basic-neuroscience research rather than direct therapeutic translation. Selective kappa-opioid agonists (difelikefalin / Korsuva for uremic pruritus) and selective small-molecule mu agonists are the clinical translations of the endogenous opioid pharmacology rather than the peptides themselves. The conceptual and pharmacological framework defined by endogenous opioid discovery remains foundational for opioid drug development.
What is kyotorphin and how is it different from morphine?
Kyotorphin is an endogenous dipeptide (Tyr-Arg) characterized by Hiroshi Takagi at Kyoto University in 1979 with morphine-like analgesic activity in rodent models — but with a distinctive indirect mechanism. Kyotorphin does not bind classical mu, delta, or kappa opioid receptors directly. Instead, it acts at a kyotorphin-preferring receptor (incompletely characterized at the molecular level) that triggers Met-enkephalin release, with the released enkephalin then binding mu and delta opioid receptors to produce analgesia. The downstream pharmacology is therefore opioid-receptor-mediated (naloxone-reversible) but the upstream mechanism is fundamentally distinct from morphine's direct mu-opioid agonism. Kyotorphin has not been clinically developed as an analgesic because of pharmacokinetic limitations of the dipeptide. See the Kyotorphin peptide page for the full account.
What is casomorphin and is it really a milk opioid?
Yes — casomorphin (specifically beta-casomorphin-7, BCM-7) is a real opioid-active peptide released by gastrointestinal digestion of bovine beta-casein, characterized by Brantl, Henschen, Teschemacher and colleagues at the Max-Planck-Institut in 1979. BCM-7 binds mu-opioid receptors in receptor-binding assays with low-micromolar affinity — substantially weaker than morphine but pharmacologically real. The clinical relevance is the principal element of the long-running A1-vs-A2-milk debate: bovine beta-casein has two genetic variants (A1 with histidine at position 67, A2 with proline) that differ in BCM-7 release efficiency during digestion. A2-only milk releases negligible BCM-7. The broader claims about BCM-7 and human disease (autism, schizophrenia, type 1 diabetes, cardiovascular disease) have not been supported by rigorous evidence; EFSA's 2009 review concluded that a causal relationship was not established. See the Casomorphin peptide page for the full account.
Why don't endogenous opioids cause addiction the way morphine does?
They actually can — the endogenous opioid system is fundamentally involved in reward circuitry, and exogenous opioid administration produces tolerance and dependence by hijacking this system. The reason endogenous opioids don't typically produce addiction in normal physiology is that the natural release pattern is tightly regulated — pulsatile, context-specific, and integrated with feedback mechanisms that prevent the sustained receptor occupation characteristic of exogenous opioid use. Exogenous opioid drugs produce sustained, supraphysiological mu-receptor activation that overwhelms the natural regulatory loops and drives the receptor downregulation, tolerance, and dependence that define opioid use disorder. The endogenous opioids are essential to normal pain modulation, reward, and stress response without typically producing addiction-relevant behaviors — but the same receptor system is what addiction medicine drugs (naloxone, naltrexone, buprenorphine, methadone) target.
References
- Identification of two related pentapeptides from the brain with potent opiate agonist activityOriginal Research
Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, and Morris HR, Nature 1975. The discovery paper isolating Met-enkephalin and Leu-enkephalin from porcine brain at the University of Aberdeen, demonstrating that the brain produces its own pentapeptide opiate-like agonists. Foundational paper of the endogenous opioid peptide field — earned Hughes and Kosterlitz a share of the 1978 Albert Lasker Award alongside Solomon Snyder.
- Dynorphin-(1-13), an extraordinarily potent opioid peptideOriginal Research
Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, and Hood L, Proceedings of the National Academy of Sciences 1979. The discovery paper isolating dynorphin-(1-13) — the endogenous kappa-opioid agonist with extraordinary potency, distinguished from the mu/delta-focused pharmacology of the earlier-discovered enkephalins and beta-endorphin. Established the kappa-opioid branch of the endogenous opioid family.